Biotest AG — M&A Activity 2005

Jun 28, 2005

News Details

Corporate | 28 June 2005 11:14

Biotest AG and Boehringer Ingelheim Enter Into Collaboration Agreement

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Biotest AG and Boehringer Ingelheim Enter Into Collaboration Agreement Dreieich, June 28, 2005. Biotest AG and Boehringer Ingelheim have concluded an agreement in June 2005 for a joint research effort to investigate the efficacy of the monoclonal antibody BT-061 in animal models of asthma. BT-061 is directed against a target on T-cells mediating a unique, immunoregulatory mode of action. Previous studies conducted in the collaborative partnership between Biotest and Boehringer have confirmed the special properties of BT-061 compared to 15 other monoclonal antibodies. The candidate is Biotest’s most advanced monoclonal antibody and has shown promising results in early clinical trials in patients with rheumatoid arthritis and psoriasis. Biotest develops the antibody in these autoimmune diseases and currently produces material to continue clinical development. The immunomodulatory properties of BT-061 provide the scientific rationale to use this candidate in autoimmune diseases, asthma and allergic diseases. Due to its TNF-independent mode of action, BT-061 is not limited to diseases such as rheumatoid arthritis and psoriasis in which the cytokine TNF plays a major role. This is in contrast to anti-TNF therapeutics, a class of biopharmaceuticals that is already very successful, but can not be used in TNF-independent diseases. Accordingly, both companies, Boehringer Ingelheim and Biotest, are very keen on exploring the additional potential of the antibody. About Biotest AG Biotest AG, Dreieich, is a fully integrated pharmaceutical and diagnostics company with approximately 1,000 employees world-wide. Biotest is specialized in the development, production and marketing of therapeutic and diagnostic systems with a focus on clinical immunology, autoimmune diseases, haematology and intensive care medicine. The product portfolio includes human plasma derivatives such as immunoglobulin preparations and blood factors as well as test systems for cell diagnosis, transfusion diagnosis and tests for hygiene monitoring. In addition to further innovative plasma derivatives, Biotest’s therapeutic pipeline comprises several monoclonal antibody candidates. Biotest AG’s shares are admitted to Prime Standard trading. For more information please visit www.biotest.com. About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2004, Boehringer Ingelheim posted net sales of 8.2 billion euro while spending nearly one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com Investor Relations: Hubert Bötsch, Phone: +49 (0) 6103 801-444, Telefax: +49 (0) 6103 801-880, E-Mail: hubert_boetsch@biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.com WKN, ISIN Stammaktie: 522720, DE0005227201 WKN, ISIN Vorzugsaktie: 522723, DE0005227235 Notiert: Prime Standard/Amtlicher Handel Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart End of announcement (c)DGAP 28.06.2005 —————————————————————————— WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 281114 Jun 05